mTOR inhibitors in cancer therapy
The mammalian target of rapamycin (mTOR) plays a key role in regulation of cellular metabolism, growth, and proliferation. The frequent hyperactivation of mTOR signaling makes it an attractive target for therapeutic intervention and has driven the development of a number of mTOR inhibitors. Encourag...
Gespeichert in:
| Veröffentlicht in: | Cancer letters 2012-06, Vol.319 (1), p.1-7 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 7 |
|---|---|
| container_issue | 1 |
| container_start_page | 1 |
| container_title | Cancer letters |
| container_volume | 319 |
| creator | Zaytseva, Yekaterina Y Valentino, Joseph D Gulhati, Pat Mark Evers, B |
| description | The mammalian target of rapamycin (mTOR) plays a key role in regulation of cellular metabolism, growth, and proliferation. The frequent hyperactivation of mTOR signaling makes it an attractive target for therapeutic intervention and has driven the development of a number of mTOR inhibitors. Encouraging data from preclinical studies have resulted in initiation of multiple clinical trials. Furthermore, combinational strategies are being studied in an effort to overcome resistance and enhance efficacy. Although additional studies are required to determine their specific role in the clinical setting, mTOR inhibitors remain a promising therapeutic option for the treatment of cancer. |
| doi_str_mv | 10.1016/j.canlet.2012.01.005 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_928372293</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0304383512000304</els_id><sourcerecordid>928372293</sourcerecordid><originalsourceid>FETCH-LOGICAL-c468t-d30c0dc28861af3c0c20b1ab3aebe57367b8dfcf02f3d2d4c298256ddcc9e16c3</originalsourceid><addsrcrecordid>eNqFkU1v1DAQhi0EotvCP0CwiAOnhLEdO84FCVWUIlWq1I-z5Ywn1Es2Wews0v77Ok0BqRdOnsMzr2eeYewNh5ID1582Jbqhp6kUwEUJvARQz9iKm1oUdWPgOVuBhKqQRqojdpzSBjJR1eolOxJCaC6lXrH325vLq3UY7kIbpjGmXK5zLlJcT3cU3e7wir3oXJ_o9eN7wm7Pvt6cnhcXl9--n365KLDSZiq8BASPwhjNXScRUEDLXSsdtaRqqevW-A47EJ30wlcoGiOU9h6xIa5RnrCPS-4ujr_2lCa7DQmp791A4z7ZRhhZC9HITH54Qm7GfRzycJYr0FAr3ahMVQuFcUwpUmd3MWxdPFgOdjZoN3YxaGeDFrjNfnLb28fwfbsl_7fpj7IMvFuAzo3W_Ygh2dvrnKCyXimah58_LwRlXb8DRZswUHbqQyScrB_D_2Z4GoB9GAK6_icdKP3b1qbcY6_nO89n5mKeIdf3qJefXw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1506075695</pqid></control><display><type>article</type><title>mTOR inhibitors in cancer therapy</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Zaytseva, Yekaterina Y ; Valentino, Joseph D ; Gulhati, Pat ; Mark Evers, B</creator><creatorcontrib>Zaytseva, Yekaterina Y ; Valentino, Joseph D ; Gulhati, Pat ; Mark Evers, B</creatorcontrib><description>The mammalian target of rapamycin (mTOR) plays a key role in regulation of cellular metabolism, growth, and proliferation. The frequent hyperactivation of mTOR signaling makes it an attractive target for therapeutic intervention and has driven the development of a number of mTOR inhibitors. Encouraging data from preclinical studies have resulted in initiation of multiple clinical trials. Furthermore, combinational strategies are being studied in an effort to overcome resistance and enhance efficacy. Although additional studies are required to determine their specific role in the clinical setting, mTOR inhibitors remain a promising therapeutic option for the treatment of cancer.</description><identifier>ISSN: 0304-3835</identifier><identifier>EISSN: 1872-7980</identifier><identifier>DOI: 10.1016/j.canlet.2012.01.005</identifier><identifier>PMID: 22261336</identifier><language>eng</language><publisher>Ireland: Elsevier Ireland Ltd</publisher><subject>Antineoplastic Agents - therapeutic use ; Biosynthesis ; Cancer ; Cancer therapy ; Cell growth ; Clinical trials ; Drug resistance ; Feedback ; Hematology, Oncology and Palliative Medicine ; Humans ; Kinases ; Lymphoma ; mammals ; metabolism ; Molecular Targeted Therapy ; mTOR ; Neoplasms - drug therapy ; Neoplasms - metabolism ; Phosphatidylinositol 3-Kinases - antagonists & inhibitors ; Phosphorylation ; Protein synthesis ; Proteins ; Regulation ; Rodents ; Signal Transduction ; therapeutics ; TOR Serine-Threonine Kinases - antagonists & inhibitors ; TOR Serine-Threonine Kinases - physiology ; Tumors</subject><ispartof>Cancer letters, 2012-06, Vol.319 (1), p.1-7</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2012 Elsevier Ireland Ltd</rights><rights>Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Jun 1, 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c468t-d30c0dc28861af3c0c20b1ab3aebe57367b8dfcf02f3d2d4c298256ddcc9e16c3</citedby><cites>FETCH-LOGICAL-c468t-d30c0dc28861af3c0c20b1ab3aebe57367b8dfcf02f3d2d4c298256ddcc9e16c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.canlet.2012.01.005$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,45974</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22261336$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zaytseva, Yekaterina Y</creatorcontrib><creatorcontrib>Valentino, Joseph D</creatorcontrib><creatorcontrib>Gulhati, Pat</creatorcontrib><creatorcontrib>Mark Evers, B</creatorcontrib><title>mTOR inhibitors in cancer therapy</title><title>Cancer letters</title><addtitle>Cancer Lett</addtitle><description>The mammalian target of rapamycin (mTOR) plays a key role in regulation of cellular metabolism, growth, and proliferation. The frequent hyperactivation of mTOR signaling makes it an attractive target for therapeutic intervention and has driven the development of a number of mTOR inhibitors. Encouraging data from preclinical studies have resulted in initiation of multiple clinical trials. Furthermore, combinational strategies are being studied in an effort to overcome resistance and enhance efficacy. Although additional studies are required to determine their specific role in the clinical setting, mTOR inhibitors remain a promising therapeutic option for the treatment of cancer.</description><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biosynthesis</subject><subject>Cancer</subject><subject>Cancer therapy</subject><subject>Cell growth</subject><subject>Clinical trials</subject><subject>Drug resistance</subject><subject>Feedback</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Kinases</subject><subject>Lymphoma</subject><subject>mammals</subject><subject>metabolism</subject><subject>Molecular Targeted Therapy</subject><subject>mTOR</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - metabolism</subject><subject>Phosphatidylinositol 3-Kinases - antagonists & inhibitors</subject><subject>Phosphorylation</subject><subject>Protein synthesis</subject><subject>Proteins</subject><subject>Regulation</subject><subject>Rodents</subject><subject>Signal Transduction</subject><subject>therapeutics</subject><subject>TOR Serine-Threonine Kinases - antagonists & inhibitors</subject><subject>TOR Serine-Threonine Kinases - physiology</subject><subject>Tumors</subject><issn>0304-3835</issn><issn>1872-7980</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU1v1DAQhi0EotvCP0CwiAOnhLEdO84FCVWUIlWq1I-z5Ywn1Es2Wews0v77Ok0BqRdOnsMzr2eeYewNh5ID1582Jbqhp6kUwEUJvARQz9iKm1oUdWPgOVuBhKqQRqojdpzSBjJR1eolOxJCaC6lXrH325vLq3UY7kIbpjGmXK5zLlJcT3cU3e7wir3oXJ_o9eN7wm7Pvt6cnhcXl9--n365KLDSZiq8BASPwhjNXScRUEDLXSsdtaRqqevW-A47EJ30wlcoGiOU9h6xIa5RnrCPS-4ujr_2lCa7DQmp791A4z7ZRhhZC9HITH54Qm7GfRzycJYr0FAr3ahMVQuFcUwpUmd3MWxdPFgOdjZoN3YxaGeDFrjNfnLb28fwfbsl_7fpj7IMvFuAzo3W_Ygh2dvrnKCyXimah58_LwRlXb8DRZswUHbqQyScrB_D_2Z4GoB9GAK6_icdKP3b1qbcY6_nO89n5mKeIdf3qJefXw</recordid><startdate>20120601</startdate><enddate>20120601</enddate><creator>Zaytseva, Yekaterina Y</creator><creator>Valentino, Joseph D</creator><creator>Gulhati, Pat</creator><creator>Mark Evers, B</creator><general>Elsevier Ireland Ltd</general><general>Elsevier Limited</general><scope>FBQ</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20120601</creationdate><title>mTOR inhibitors in cancer therapy</title><author>Zaytseva, Yekaterina Y ; Valentino, Joseph D ; Gulhati, Pat ; Mark Evers, B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c468t-d30c0dc28861af3c0c20b1ab3aebe57367b8dfcf02f3d2d4c298256ddcc9e16c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biosynthesis</topic><topic>Cancer</topic><topic>Cancer therapy</topic><topic>Cell growth</topic><topic>Clinical trials</topic><topic>Drug resistance</topic><topic>Feedback</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Kinases</topic><topic>Lymphoma</topic><topic>mammals</topic><topic>metabolism</topic><topic>Molecular Targeted Therapy</topic><topic>mTOR</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - metabolism</topic><topic>Phosphatidylinositol 3-Kinases - antagonists & inhibitors</topic><topic>Phosphorylation</topic><topic>Protein synthesis</topic><topic>Proteins</topic><topic>Regulation</topic><topic>Rodents</topic><topic>Signal Transduction</topic><topic>therapeutics</topic><topic>TOR Serine-Threonine Kinases - antagonists & inhibitors</topic><topic>TOR Serine-Threonine Kinases - physiology</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zaytseva, Yekaterina Y</creatorcontrib><creatorcontrib>Valentino, Joseph D</creatorcontrib><creatorcontrib>Gulhati, Pat</creatorcontrib><creatorcontrib>Mark Evers, B</creatorcontrib><collection>AGRIS</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zaytseva, Yekaterina Y</au><au>Valentino, Joseph D</au><au>Gulhati, Pat</au><au>Mark Evers, B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>mTOR inhibitors in cancer therapy</atitle><jtitle>Cancer letters</jtitle><addtitle>Cancer Lett</addtitle><date>2012-06-01</date><risdate>2012</risdate><volume>319</volume><issue>1</issue><spage>1</spage><epage>7</epage><pages>1-7</pages><issn>0304-3835</issn><eissn>1872-7980</eissn><abstract>The mammalian target of rapamycin (mTOR) plays a key role in regulation of cellular metabolism, growth, and proliferation. The frequent hyperactivation of mTOR signaling makes it an attractive target for therapeutic intervention and has driven the development of a number of mTOR inhibitors. Encouraging data from preclinical studies have resulted in initiation of multiple clinical trials. Furthermore, combinational strategies are being studied in an effort to overcome resistance and enhance efficacy. Although additional studies are required to determine their specific role in the clinical setting, mTOR inhibitors remain a promising therapeutic option for the treatment of cancer.</abstract><cop>Ireland</cop><pub>Elsevier Ireland Ltd</pub><pmid>22261336</pmid><doi>10.1016/j.canlet.2012.01.005</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0304-3835 |
| ispartof | Cancer letters, 2012-06, Vol.319 (1), p.1-7 |
| issn | 0304-3835 1872-7980 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_928372293 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Antineoplastic Agents - therapeutic use Biosynthesis Cancer Cancer therapy Cell growth Clinical trials Drug resistance Feedback Hematology, Oncology and Palliative Medicine Humans Kinases Lymphoma mammals metabolism Molecular Targeted Therapy mTOR Neoplasms - drug therapy Neoplasms - metabolism Phosphatidylinositol 3-Kinases - antagonists & inhibitors Phosphorylation Protein synthesis Proteins Regulation Rodents Signal Transduction therapeutics TOR Serine-Threonine Kinases - antagonists & inhibitors TOR Serine-Threonine Kinases - physiology Tumors |
| title | mTOR inhibitors in cancer therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T18%3A50%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=mTOR%20inhibitors%20in%20cancer%20therapy&rft.jtitle=Cancer%20letters&rft.au=Zaytseva,%20Yekaterina%20Y&rft.date=2012-06-01&rft.volume=319&rft.issue=1&rft.spage=1&rft.epage=7&rft.pages=1-7&rft.issn=0304-3835&rft.eissn=1872-7980&rft_id=info:doi/10.1016/j.canlet.2012.01.005&rft_dat=%3Cproquest_cross%3E928372293%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1506075695&rft_id=info:pmid/22261336&rft_els_id=S0304383512000304&rfr_iscdi=true |